08 October 2026
From Evidence to Action: Advancing Care in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome
CME
About
Faculty: Dr. Ioanna Gouni-Berthold, MD
Faculty: Gerald Watts, MD, PhD
Faculty: Gerald Watts, MD, PhD
How should emerging APOC3-targeted therapies change the conversation around severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS)? Drs. Gerald Watts and Ioanna Gouni-Berthold examine findings from SHASTA-3, SHASTA-4, CORE, CORE2, PALISADE, and BALANCE, with a focus on triglyceride lowering, acute pancreatitis, and safety. Hear how the experts interpret emerging data in sHTG alongside advances in FCS treatment and translate the evidence into patient-centered clinical decision-making while avoiding inappropriate cross-trial comparisons.